Resource Library
Redefining BsAb development with structural innovation and enhanced manufacturability
Bispecific antibodies (bsAbs) play a unique role in reducing off-target effects, enhancing selectivity, and improving pharmacodynamics. Despite their therapuetic potential, the development of bsAbs can pose challenges in the purification process during manufacturing, such as mispairing during assembly.
Through improved molecular design to promote correct chain pairing, optimized bioprocessing techniques, and advanced analytical methods to ensure high product purity and efficacy, Samsung Biologics’ S-KiH platform ensures bsAb manufacturability. S-KiH streamlines the bsAb manufacturing process, reducing costs and enhacing overall clinical viability.
In combination with S-DUAL™, S-KiH can accelerate the development of next-generation bsAb therapeutics, making them more accessible and scalable for diverse medical applications. Learn more in our latest whitepaper.
Bispecific antibodies (bsAbs) play a unique role in reducing off-target effects, enhancing selectivity, and improving pharmacodynamics. Despite their therapuetic potential, the development of bsAbs can pose challenges in the purification process during manufacturing, such as mispairing during assembly.
Through improved molecular design to promote correct chain pairing, optimized bioprocessing techniques, and advanced analytical methods to ensure high product purity and efficacy, Samsung Biologics’ S-KiH platform ensures bsAb manufacturability. S-KiH streamlines the bsAb manufacturing process, reducing costs and enhacing overall clinical viability.
In combination with S-DUAL™, S-KiH can accelerate the development of next-generation bsAb therapeutics, making them more accessible and scalable for diverse medical applications. Learn more in our latest whitepaper.